Test Code Epic LAB787 Lyme Disease Antibody, Immunoblot, Serum
Additional Codes
SQ code LYMECM
Mayo code LYWB
Reporting Name
Lyme Disease Ab, Immunoblot, SSpecimen Type
SerumPerforming Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Aiding in the diagnosis of systemic Lyme disease
This test should not be used as a screening assay.
Testing Algorithm
For information see Acute Tick-Borne Disease Testing Algorithm.
Specimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume:0.75 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 14 days | |
Frozen | 30 days |
Reference Values
IgG: Negative
IgM: Negative
Reference values apply to all ages
Day(s) Performed
Monday, Wednesday, Friday
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86617 x 2
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
LYWB | Lyme Disease Ab, Immunoblot, S | 18203-0 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
5744 | IgG Immunoblot | 6320-6 |
2992 | IgG detected against: | 13502-0 |
23931 | IgM Immunoblot | 6321-4 |
23932 | IgM detected against: | 13503-8 |
6241 | Interpretation | 12781-1 |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Heat-inactivated specimen | Reject |
Method Name
Immunoblot Microarray
Method Description
The Viramed Biotech AG Borrelia B31 ViraChip IgM and IgG are protein microarray assays and can be considered modified solid-phase enzyme-linked immunosorbent assays. Highly purified antigens from the Borrelia burgdorferi B31 strain, including the 93 kD, 66 kD, 58 kD, 45 kD, 41 kD, 39 kD, 30 kD, 28 kD, 23 kD, and 18 kD proteins, are bound to the solid phase nitrocellulose membrane in triplicate. The positions of these antigen "spots" are well defined and are reliably identifiable using customized software. Each microarray also has "spots" for a negative control, serum controls, conjugate controls, and 6 calibrators. One microarray is fixed to the bottom of a well in a standard 96-well microtiter plate.
For each test to be performed, the diluted patient serum is added to each microarray (note: the B burgdoreri IgG and IgM microarrays are in separate wells). If specific antibodies recognizing a B burgdorferi antigen are present, they will bind to the specific antigens on the microarray. After incubation, the microarray is washed to remove unbound antibodies. Alkaline-phosphatase antihuman IgG or antihuman IgM (conjugate) is then added to the well and incubated. If antibodies are present, the conjugate will bind to those respective antibodies, and after a washing step to remove unbound conjugate, substrate solution is added. If the antibody/conjugate complex is present, the substrate will undergo precipitation and color change. After an incubation period, the reaction is stopped, and the presence of precipitated substrate is visualized at specific locations on the microarray. The presence of a colored precipitation at various locations on the microarray is an indirect measurement of B burgdorferi specific antibodies in the patient specimen. Visualized spots from the reaction are compared for intensity with the integrated calibrator controls for evaluation.(Package inserts: Borrelia B31 ViraChip IgM and Borrelia B31 ViraChip IgG. VIRAMED Biotech AG; 01/2018)
Report Available
Same day/1 to 4 daysForms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-General Request (T239)